Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,746.50
Bid: 1,742.50
Ask: 1,743.00
Change: 6.50 (0.37%)
Spread: 0.50 (0.029%)
Open: 1,730.00
High: 1,746.50
Low: 1,729.00
Prev. Close: 1,740.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday share tips: EasyJet, Randgold, Imperial Brands, AstraZeneca

Sun, 26th Jun 2016 14:03

(ShareCast News) - Sell EasyJet shares due to the likely turbulence sparked by the Brexit vote, said the Sunday Times' Inside the City column. The budget airline was created by Stelios Haji-Ioannou in the wake of the 1992 European Union Treaty on Open Skies, one of the supposedly rare bits of Brussels red tape that did away with restrictive rules that favoured national carriers and opened up the market. With uncertainty about how it will operate once the UK leaves the EU, its shares flew 14% lower on Friday. On the day of the referendum result, EasyJet that it had been "preparing for this eventuality in the lead up to the referendum vote and has been working on a number of options that will allow it to continue flying in all of its markets".The best case for the company, the column said, was that the UK manages to remain inside the EU aviation market, but it would require a great feat of negotiation. Either way, with sterling worth less against the euro, overseas trips become pricier. And if the UK slips into recession, this will also hit demand. The company's dividend hike announced in May was predicated on management confidence of growing passenger numbers and profits in 2016. While the share are healthily priced after their fall, the journey ahead will not be a smooth one.Investors should keep calm and head for safe haven stocks like precious metals and tobacco giants, insisted Questor in the Sunday Telegraph, after the Brexit vote sent stock markets tumbling. Good Investors who had sold as stocks hurtled south could have locked in losses before many blue-chip shares rebounded. Although the long-term investing outlook has dimmed, sending the pound and equities down driving for government bonds, hasty decisions are often regretted. There will be an impact on the City of London position as the uncertainty over the UK's future diverts some money elsewhere.Bonds, both government and corporate, remain an appealing investment. Shares may make a tentative recovery now that the deed is done, but as the implications sink in, with a UK recession possible, it will not last long. Three times in recent months the column has advised selling the house-building sector and even with the shares now cheaper, the outlook is worse post-Brexit. Metals miners Randgold ad Fresnillo, as recommended last week, remain attractive, likewise gold-focused ETFs. For income and a good level of exposure to US dollar earnings, drugmakers AstraZeneca and GlaxoSmithKline, cigarette companies British American Tobacco and Imperial Brands, as well as National Grid. Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only and not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.